Literature DB >> 7886761

Use of the leishmanin skin test and western blot analysis for epidemiological studies in visceral leishmaniasis areas: experience in a highly endemic focus in Alpes-Maritimes (France).

P Marty1, A Lelievre, J F Quaranta, A Rahal, M Gari-Toussaint, Y Le Fichoux.   

Abstract

Fifty unselected subjects living in Alpes-Maritimes, France, a high risk area for visceral leishmaniasis due to Leishmania infantum, were examined simultaneously by the leishmanin skin test and the Western blot technique in 1993; 32% and 38%, respectively, gave a positive reaction. The concordance of the 2 methods was 82%. Thus, in this high risk area, a large proportion of inhabitants had been exposed to the parasite. The use of these 2 tests should permit the detection of potential cases of reactivated leishmaniasis in prospective follow-up investigations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7886761     DOI: 10.1016/0035-9203(94)90214-3

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  19 in total

1.  Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis.

Authors:  R Kumar; K Pai; K Pathak; S Sundar
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

2.  A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis.

Authors:  I Suffia; B Ferrua; X Stien; B Mograbi; P Marty; D Rousseau; K Fragaki; J Kubar
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia.

Authors:  A Sassi; H Louzir; A Ben Salah; M Mokni; A Ben Osman; K Dellagi
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis.

Authors:  M Soto; J M Requena; L Quijada; M J Perez; C G Nieto; F Guzman; M E Patarroyo; C Alonso
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

5.  Subclinical Leishmania infection in patients with rheumatic diseases under biological drugs.

Authors:  Martina Maritati; Alessandro Trentini; Gregory Michel; Tiziana Bellini; Shawgi Almugadam; Stefania Hanau; Marcello Govoni; Pierre Marty; Carlo Contini
Journal:  Infection       Date:  2018-08-10       Impact factor: 3.553

6.  Performance of immunoblotting in diagnosis of visceral Leishmaniasis in human immunodeficiency virus-Leishmania sp.-coinfected patients.

Authors:  G Santos-Gomes; S Gomes-Pereira; L Campino; M D Araújo; P Abranches
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

7.  Strategies for reducing the risk of transfusion-transmitted leishmaniasis in an area endemic for Leishmania infantum: a patient- and donor-targeted approach.

Authors:  Teresa Jimenez-Marco; Cristina Riera; Enrique Girona-Llobera; Carmen Guillen; Laura Iniesta; Magdalena Alcover; Diana Berenguer; Alba Pujol; Miriam Tomás-Pérez; Beatriz Cancino-Faure; Teresa Serra; Martín Mascaró; Joan Gascó; Roser Fisa
Journal:  Blood Transfus       Date:  2017-03-15       Impact factor: 3.443

8.  Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon- and interleukin-5-producing CD4(+) antigen-specific T cells.

Authors:  C Mary; V Auriault; B Faugère; A J Dessein
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

9.  Human T-cell activation by 14- and 18-kilodalton nuclear proteins of Leishmania infantum.

Authors:  I Suffia; J F Quaranta; M C Eulalio; B Ferrua; P Marty; Y Le Fichoux; J Kubar
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

10.  Asymptomatic Leishmania infantum infection in an area of northwestern Italy (Piedmont region) where such infections are traditionally nonendemic.

Authors:  Alberto Biglino; Cesare Bolla; Erika Concialdi; Anna Trisciuoglio; Angelo Romano; Ezio Ferroglio
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.